Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a prominent player in the health care equipment and supplies sector, has recently completed its investor-relations activities for the fourth quarter of 2025. This filing, made public through a regulatory document, confirms the company’s adherence to its reporting obligations for the year-end quarter. The announcement, however, did not include any additional operational or financial updates.
As a subsidiary of Mindray Medical International Limited, Shenzhen Mindray Bio-Medical Electronics Co. Ltd. operates primarily on the Shenzhen Stock Exchange, with its shares traded in Chinese Yuan (CNY). The company’s close price on December 30, 2025, was recorded at 190.45 CNY, marking both the 52-week low and the closing price for that day. The 52-week high for the company was observed on February 16, 2025, at 267.1 CNY. With a market capitalization of approximately 230.91 billion CNY, the company maintains a price-to-earnings ratio of 26.82.
Founded in 1991 and headquartered in Shenzhen, China, Shenzhen Mindray Bio-Medical Electronics Co. Ltd. is renowned for its extensive range of medical equipment and supplies. The company’s offerings encompass patient monitoring systems, electrocardiographs, defibrillators, anesthesia machines, ventilators, infusion pumps, surgical lights, operating tables, medical supply units, endoscopes, and various accessories. Additionally, the company provides solutions for emergency care, peri-operative care, critical care, and IT solutions.
The company’s in-vitro diagnostics portfolio includes hematology and chemistry analyzers, reagents, chemiluminescence immunoassay products, flow cytometry products, hemoglobin systems, and micro plate readers and washers. Furthermore, Shenzhen Mindray Bio-Medical Electronics Co. Ltd. offers medical imaging systems, such as ultrasound and radiology products, as well as veterinary products.
While the recent filing did not disclose specific performance metrics or strategic initiatives, it highlights the company’s ongoing commitment to regulatory compliance and investor engagement within the Chinese capital market. This underscores Mindray’s dedication to maintaining transparency and fostering trust among its stakeholders.
